Our analyses showed that lower CETP concentration was associated with a lower risk of CHD (OR 0.95 per μg/ml lower CETP concentration; 95% CI: 0.91–0.99), HF (OR 0.95; 95% CI: 0.92–0.99), and CKD (OR 0.94; 95% CI: 0.91–0.98), CKD (OR 0.94, 95% CI: 0.91–0.97) and a higher risk of AMD (OR 1.31, 95% CI: 1.22–1.40). This evidence concerns the gene CETP and chronic kidney disease.